Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Nice.

Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate. The West Coast startup relied heavily on tech VCs for the cash, but also gained validation from having CRISPR pioneer Jennifer Doudna invest in its business.

Redwood City, CA-based Synthego exited stealth in August, four years after it was set up by two former SpaceX computer engineers. In those early years, which were bankrolled by an $8.3 million investment in 2013, Synthego established an automated manufacturing process for guide RNA products that it thinks sets it apart from larger competitors in terms of cost, turnaround time and editing efficiency.

Sythengo has persuaded some big names it is on to something. 8VC, an infrastructure-focused VC that also invested in uBiome, led the round with support from fellow new backers AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities and ZhenFund. Existing investors including Peter Thiel’s Founders Fund and Menlo Ventures also contributed to the Series B round.

Read more

Let’s show them we appreciate! smile

Removing senescent cells could help reduce age-related diseases and improve health. You have the power to help shape the future of medicine by supporting the CellAge campaign at lifespan.io check it out on the link below:

https://www.lifespan.io/campaigns/cellage-targeting-senescent-cells-with-synthetic-biology/

Read more

For just $25 your name will be converted into cool DNA coding language and placed in the special CellAge time capsule for a future generation to discover!

Your donation could help us to develop cures for age-related diseases, check out the CellAge project on Lifespan.io today.

https://www.lifespan.io/campaigns/cellage-targeting-senescent-cells-with-synthetic-biology/

Read more

Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.

green-cell

“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

gene-sequencing

The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.

“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”

bqaproduction

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm

In Brief

  • Microsoft is partnering with a prestigious eye hospital in India to help perfect AI powered computer diagnostics to the field of ophthalmology.
  • Artificial intelligence is continually making great strides to integrate more in various healthcare settings, hopefully increasing the quality and availability of patient care.

According to the World Health Organization, an estimated 285 million people are visually impaired, with 39 million living with blindness and the other 246 million having low vision.

In a world of modern technological advancements, visual impairment has been the subject of much medical research. Perhaps the most notable among these are those that use artificial intelligence (AI), specifically through machine learning. Google’s DeepMind has been working with the UK’s National Health Service to do ophthalmology research.

Read more

In Brief CRISPR has opened up limitless avenues for genetic modification. From disease prevention to invasive species control, Jennifer Kahn discusses the discover, application, and implications of gene drives.

Jennifer Kahn, a science journalist for the New York Times, recently did a TED Talk in which she discussed the discovery, application, and implications of a CRISPR gene drive used to make mosquitoes resistant to malaria and other diseases like chikungunya, and Zika.

Watch the talk in the video below, and learn how geneticists are achieving the (seemingly) impossible:

Read more